17,261 trials
Lymphoma, Large B-Cell, Diffuse
Primary: Number of Patients With Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) Evaluation Period- Phase 1b — 0; 1; 1 participants
Dengue Fever · Dengue Hemorrhagic Fever
Primary: Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD64 Compared to Third CYD Dengue Vaccine…
Dengue Fever · Dengue Hemorrhagic Fever
Primary: Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Booster Injection With CYD Dengue Vaccine in CYD63 Compared to the Third CYD…
Neurotrophic Keratitis
Primary: Complete Healing of the Persistent Epithelial Defect (PED) or Corneal Ulcer Defined by Central Reviewer — 70; 29; 30; 71 percentage of participants — p==0.006
Uterine Fibroids
Primary: Percentage of Participants in Amenorrhea at the End of Treatment Course 1 — 0.0; 53.8; 46.7 percentage of participants — p=0.0019
Acquired Hypogonadotropic Hypogonadism · Obesity
Primary: Change From Baseline in Lean Body Mass (LBM) at Week 48 — 65.23; 65.60; 68.12; 3.14 kg — p=0.7103
Gastric Cancer · Pancreatic Cancer
Primary: Number of Study Participants With Adequate Percutaneous Lavage Specimen Collection — 70; 2; 4 Participants
Alzheimer's Disease · Mild Cognitive Impairment
Primary: Percent Change From Baseline in Amyloid Plaque Burden by 11C-PiB PET — -4.57; 4.57 percentage change from baseline
Nocturia
Primary: Change in Nocturia Episodes — 3.6; 3.3; 3.9; 3.6 average nightly voids — p=0.0017
Dengue · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2 — 5.38…
Ovarian Cancer
Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0; 0 Participants
Pancreatic Cancer Metastatic
Primary: Progression Free Survival (PFS) — 4 months
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
Primary: Percentage of Participants With Complete Response (CR) at End of Induction (EOI), as Determined by the Independent Review Committee (IRC) Using Modified Lugano 2014…
Anemia · Myelodysplastic Syndromes · Chronic Myelomonocytic Leukemia
Primary: Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate) — 0; 66.7; 42.9…
Frailty
Primary: Kilocalories Consumed — 412; 553 Kilocalorie